Alzheimer's Risk Detection Kit
Based on novel monoclonal antibody (world-wide patent application submitted), the AD Early Risk Detection kit (AD Detect) consists of two complementary ELISAs for reliable (>95% ) diagnostics of early dementia stages. Our clinical studies are conducted in Amsterdam and Shanghai. In the comparative clinical study in Shanghai, our AD Detect showed superior performance compared to other blood biomarkers.